Overview

POSE2.0 With GLP-1 Agonist for Obesity Management

Status:
Recruiting

Trial end date:
2026-01-03

Target enrollment:

Participant gender:

Summary

Determine the effect on weight loss and obesity-related comorbidities in patients receiving the POSE 2.0 procedure with sequential use of Liraglutide at 6 months compared to those receiving Liraglutide and then undergoing the POSE 2.0 procedure at 6 months.

Phase:

N/A

Details

Lead Sponsor:

Emirates Health Services (EHS)

Treatments:

Liraglutide